Skip to main content
S&P 5007,676.77+0.70%DOW52,361.58+0.28%NASDAQ26,169.38+0.82%BTC$80,129.00+0.25%ETH$2,324.65+0.23%GOLD$4,027.20-0.28%OIL$101.22-0.53%
Smart Investors Daily
SID Premium
XF

NASDAQ · XFOR

X4 Pharmaceuticals, Inc.

Healthcare · Biotechnology

$3.25

Up+$0.01 (+0.31%)

Updated Oct 27, 2026, 3:23 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
44.21M
P/E ratio
-0.28
Dividend yield
0.00%
52-week range
$2.43 – $4.83
Volume
701.65K
Avg. volume
894.59K

Price performance · XFOR

XFOR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

XFOR closed at $3.25 after 21 trading sessions, up 7.79% for the selected period.

Last close
$3.25
Period change
+7.79%
Period low
$2.45
Period high
$3.25
Daily close
View OHLC price history
XFOR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$3.26$3.30$3.14$3.25701.65K
Oct 23, 2026$3.16$3.25$3.02$3.24536.76K
Oct 22, 2026$2.99$3.2798$2.96$3.20594.59K
Oct 21, 2026$3.02$3.12$2.875$3.01406.91K
Oct 20, 2026$2.79$3.07$2.77$3.02593.33K
Oct 19, 2026$2.60$2.82$2.58$2.75602.98K
Oct 16, 2026$2.64$2.71$2.52$2.59967.58K
Oct 15, 2026$2.48$2.655$2.475$2.64549.84K
Oct 14, 2026$2.54$2.55$2.43$2.45705.74K
Oct 13, 2026$2.81$2.83$2.59$2.60439.6K
Oct 12, 2026$2.89$2.93$2.81$2.82404.69K
Oct 9, 2026$2.83$2.965$2.815$2.91541.23K
Oct 8, 2026$2.77$2.81$2.70$2.79836.5K
Oct 7, 2026$2.74$2.86$2.70$2.81435.38K
Oct 6, 2026$2.90$2.90$2.70$2.77642.47K
Oct 5, 2026$2.88$2.935$2.73$2.90698.1K
Oct 2, 2026$2.86$2.86$2.745$2.83911.4K
Oct 1, 2026$2.89$2.95$2.82$2.83501.49K
Sep 30, 2026$2.93$2.935$2.845$2.901.76M
Sep 29, 2026$3.01$3.055$2.895$2.901.71M
Sep 28, 2026$2.996$3.04$2.81$3.015838.4K

Latest XFOR news

The latest Smart Investors Daily articles mentioning XFOR.

Stock researchCompany · Overview

XFOR research

Overview

Company profile and research snapshot.

Company profile

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.75
Implied upside
—
Analysts
—
XFOR recent ratings
DateFirmRatingTarget
Jul 10, 2026Wells FargoOverweight—
Jun 2, 2026Leerink PartnersOutperform—
Mar 9, 2026GuggenheimBuy—
Dec 5, 2025StifelBuy—
Nov 10, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 9, 2026

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

BOSTON, Oct. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will host a virtual Investor Day on Thursday, October 29, 2026, from 10:00 a.m. to 12:00 p.m. ET. The Investor Day will feature discussions with X4 Pharmaceuticals management and key opinion leaders on mavorixafor as a potential treatment for chronic neutropenia. Management will review the current status of

Yahoo · Oct 8, 2026

X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures

X4 Pharmaceuticals (NASDAQ:XFOR) has entered into a senior secured term loan agreement worth up to $150 million with K2 HealthVentures LLC, refinancing its existing debt facility and providing additional financial flexibility as the biotechnology company advances its clinical development and commercialisation plans. The Boston-based company confirmed that an initial $80 million tranche was funded upon completion of the agreement.

Yahoo · Oct 8, 2026

X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures

- Repayment of Existing Loan Facility Completed -- Strengthens Financial Flexibility with Access to Funding for Corporate and Commercial Activities - - Expect Completion of Enrollment in Phase 3 4WARD trial by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that it has entered into a senior secured term loan facility of up to $

Yahoo · Oct 1, 2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on September 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By